SLC22A16: A Potential Drug Target and Biomarker for Diseases (G85413)

Target Name: SLC22A16

NCBI ID: G85413

SLC22A16

SLC22A16: A Potential Drug Target and Biomarker for Diseases

SLC22A16 is a protein that is expressed in various tissues throughout the body, including the brain, heart, liver, and kidneys. It is a member of the solute carrier family 22 (SLC22) and is responsible for transmitting and releasing various anions and cations across cell membranes. SLC22A16 has been identified as a potential drug target and a biomarker for various diseases, including neurological and cardiovascular disorders.

SLC22A16 is a transmembrane protein that consists of an N-terminus, a catalytic core, and a C-terminus. The N-terminus of SLC22A16 is involved in the formation of a complex with various ligands, while the C-terminus is involved in the release of ions across cell membranes. SLC22A16 has a pI of around 8.0, which makes it a hydrophilic protein that is expressed in various tissues, including the brain, heart, liver, and kidneys.

SLC22A16 has been shown to play a role in various physiological processes in the body. For example, SLC22A16 is involved in the regulation of ion and water transport in the brain, which is essential for maintaining proper cognitive function. SLC22A16 has also been shown to play a role in the regulation of ion transport in the heart, which is essential for maintaining normal heart function.

In addition to its role in cell signaling, SLC22A16 has also been shown to be involved in the development and progression of various diseases. For example, SLC22A16 has been shown to be involved in the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. SLC22A16 has also been shown to be involved in the development of cardiovascular diseases, such as heart failure and hypertension.

SLC22A16 has also been identified as a potential drug target and a biomarker for various diseases. For example, SLC22A16 has been shown to be involved in the development of neuropsychiatric diseases, such as depression and anxiety. By targeting SLC22A16 with drugs, researchers hope to treat these diseases and improve patient outcomes.

In conclusion, SLC22A16 is a protein that is expressed in various tissues throughout the body and is involved in the regulation of cell signaling and the development and progression of various diseases. As a potential drug target and biomarker, SLC22A16 has the potential to improve patient outcomes for a wide range of conditions. Further research is needed to fully understand the role of SLC22A16 in disease and to develop effective treatments.

Protein Name: Solute Carrier Family 22 Member 16

Functions: High affinity carnitine transporter; the uptake is partially sodium-ion dependent. Thought to mediate the L-carnitine secretion mechanism from testis epididymal epithelium into the lumen which is involved in the maturation of spermatozoa. Also transports organic cations such as tetraethylammonium (TEA) and doxorubicin. The uptake of TEA is inhibited by various organic cations. The uptake of doxorubicin is sodium-independent

The "SLC22A16 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC22A16 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets